Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727336 | 0.84 | HSD11B1 (0.55) | P2RX7HSD11B1TP53LMNAMAPT | |
| SCHEMBL21995682 | 0.84 | P2RX7 (0.46) | P2RX7 | |
| SCHEMBL21995674 | 0.81 | MAPK8 (0.43) | LMNAMAPT | |
| SCHEMBL21724695 | 0.81 | HSD11B1 (0.58) | P2RX7HSD11B1TP53LMNAMAPT | |
| SCHEMBL2831744 | 0.80 | P2RX7 (0.56) | P2RX7HSD11B1TP53LMNAMAPT | |
| SCHEMBL837387 | 0.80 | P2RX7 (0.49) | P2RX7HSD11B1TP53LMNAMAPT | |
| SCHEMBL15682676 | 0.79 | ROCK2 (0.40) | P2RX7LMNA | |
| SCHEMBL15682664 | 0.79 | ERCC1 (0.49) | P2RX7MAPT | |
| SCHEMBL7925042 | 0.77 | HSD11B1 (0.57) | P2RX7HSD11B1TP53LMNAMAPT | |
| SCHEMBL11621445 | 0.77 | P2RX7 (0.43) | P2RX7HSD11B1TP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387356-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-08 | — | — | US | disclosed |
| US-20200147007-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | EASTERN MICHIGAN UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387356-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | SERPINE1, PLAT, SERPINC1 | P2RX7 4572/4885HSD11B1 758/4885TP53 4555/4885 |
| US-20200147007-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | SERPINE1, PLAT, SERPINC1 | P2RX7 4572/4885HSD11B1 758/4885TP53 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.